Category Archives: Gene Therapy Clinics

Gene Therapy for CNS Disorders Market 2021 Industry Size, Share, Growth and Top Companies Analysis- Gilead (Kite Pharma), Amgen (BioVex), Novartis,…

DataIntelo recently publishes an all-inclusive report on the Global Gene Therapy for CNS Disorders Market providing a complete overview of the key aspects of the market. Gene Therapy for CNS Disorders market report makes a robust assessment regarding the current market situation and its scope, which are anticipated to impact significantly on the performance of the market during the forecast period, 2020-2027. This report includes an in-depth analysis about the COVID-19 situation and its possible impact on the market in the next few years. The report contains XX pages, which provides a precise and detailed explanation of key components and their market expansion scope in the mentioned period. The key insights about the potential size, volume, and dynamics of the market as mentioned in the report is a vital guideline that would help clients to make informed decision about their business investment plans and strategies in the market.

As per the analysis, the global Gene Therapy for CNS Disorders market was valued at USD XX million in 2019 and is projected to reach a value of USD XX million by the end of 2027, expanding at a CAGR of XX% during the forecast period.

Few of the key players mentioned in this report:

Gilead (Kite Pharma) Amgen (BioVex) Novartis Roche (Spark Therapeutics) Bluebird Bio

Get FREE Exclusive PDF Sample Copy of This Report: https://dataintelo.com/request-sample/?reportId=113131

The report covers a detailed study on key areas such as market size, scope, and growth opportunities of the global Gene Therapy for CNS Disorders market by analyzing the market trend and data available for the period prior to 2019. From this analysis, the report draws several observations and deduces about the key factors that drive or restrain the market growth, which would have a wide impact on the development and expansion of the market during the forecast period. Moreover, it covers a range of opportunities and challenges prevailing in the market that will help clients to evaluate their investment strategies.

The global Gene Therapy for CNS Disorders market report examine the major segments and sub-segmentations of the market that are classified as the product types, applications, and regions. In additional to the harsh economic impact of the COVID-19 outbreak, the report studies the dynamics of the market by analysis the key performance of each segments and the potential expansion scope of the segments in the coming years. Furthermore, the scope of the growth potential, revenue growth, product range, and pricing factors related to the global Gene Therapy for CNS Disorders market in terms of applications are thoroughly assessed in the report in a view to entail a broader picture of the market.

The report, published by DataIntelo, is the most reliable information as the study consists of a concise graphical representations, tables, and figures which allow the users to easily understand the key market position of sectors or segment without going through a deep study of the report. The tables and figures represent the latest update information that provides a broad picture of several market developments of the products and services over the last few years.

Customize Report and Inquiry for the Gene Therapy for CNS Disorders market report @ https://dataintelo.com/enquiry-before-buying/?reportId=113131

The market report relies on a concrete research methodology focusing on both primary as well as secondary sources. The report is prepared by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the private and public companies. Additionally, this report includes market analysis from several global experts and analysts who have in-depth knowledge about the market. To ensure a complete framework of the market, it also adopts several research tools such as statistical surveying for SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics.

Global Gene Therapy for CNS Disorders market by Products

Ex Vivo In Vivo

Global Gene Therapy for CNS Disorders market by Applications

Hospitals Clinics Others

You can buy the complete report in PDF format @ https://dataintelo.com/checkout/?reportId=113131

The report mentions some key global players in the market and additional names of the players in the market can be included as per the clients request. Moreover, a customized or separate report can also be available according to the needs of clients. The report covers the recent development of players including merger & acquisition agreements, partnership or joint venture and latest products launches from the key manufacturers in the Gene Therapy for CNS Disorders market. Please contact with our sales team, who will deliver reports that suits your necessities.

Competition Landscape

The report covers global aspect of the market, covering

North America Latin America Europe Asia Pacific Middle East and Africa

About DataIntelo:

DataIntelo is a globally leading distributor of market research report that has experienced by dealing with more than 800+ global clients. We offer quality market research report and provide data that can help generate a totally new approach for our clients to help change the outlook of their investment and business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

See the original post:
Gene Therapy for CNS Disorders Market 2021 Industry Size, Share, Growth and Top Companies Analysis- Gilead (Kite Pharma), Amgen (BioVex), Novartis,...

Top Executives from AveXis Join New Gene Therapy Venture — This Time Targeting Tens of Millions More Patients – PRNewswire

MADISON, Wis., March 29, 2021 /PRNewswire/ --A pair of top C-level Executives from blockbuster gene therapy company AveXis have joined ENDSULIN, a new venture that could reach millions more than any gene therapy to date. Spearheaded by one of the disease's most accomplished pioneers, the company aims to upend a multi-billion dollar treatment industry.

Both Brian Kaspar and Thomas Dee, the founding Chief Science and Chief Finance Officers, respectively, of AveXis (developer of Zolgensma, bought by Novartis for $8.7 Billionin May of 2018) have accepted board roles at ENDSULIN. While AveXis sought to "transform rare diseases," ENDSULIN is solely targeting one of the most prolific Type 1 diabetes (T1D) with what they hope will be a one-time treatment to free patients from daily insulin injections by more precisely regulating their glycemic control.

"The science itself is remarkable, but the potential to change millions of lives is unprecedented," Kaspar said. "We've proven gene therapy can revolutionize medicine with lasting, durable treatments. But now we need players like ENDSULIN with the right vision and focus who can harness that momentum to give patients the relief they deserve."

The former AveXis leaders round out a team of pioneering experts at the forefront of diabetes, gene therapy and drug development, strategically brought together to accelerate ENDSULIN's undivided focus: FDA authorization to begin human clinical trials.

Founder Hans Sollinger's previous discoveries have shaped modern pancreatic transplantation treatment for T1D. But because of the complexity of the disease, while the science of management has advanced, insulin shots have been the enduring standard of care since the 1920s almost a full century.

"25 years ago, I had performed more kidney-pancreas transplants than anyone in the world, but I'd only helped 500 people," Sollinger said. "The most important aspect of my search for a cure became its reach, in terms of both scale and accessibility. As I advanced, it became more and more obvious that gene therapy was the way to achieve it all, with no compromises."

Through decades of research at the UW Hospitals and Clinics, Sollinger's team developed a highly unique and targeted expression system that addresses one of the greatest challenges in treating T1D: precise regulation of insulin in response to rapidly fluctuating glucose levels. Several publications over the last 10 years have demonstratedlong-lasting euglycemia control in hundreds of mice and rats, indicating a durable cure may be within reach.

"We've focused everything we are doing around our mission to get this treatment to patients," said Eric Spyra, Interim CEO and Board Member. "Using existing commercial infrastructure and following the path of other liver-directed AAV gene therapies, we're putting all the pieces in place now that will accelerate this therapy through every stage."

ENDSULIN has already initiated a pilot study in autoimmune-modeled naturally diabetic companion dogs, while executing their IND-enabling plan and preclinical studies. The company is preparing for a Series A funding round this year.

ABOUT ENDSULIN ENDSULIN is reshaping the way we approach a cure for diabetes. They are working to free patients from daily injections and 24/7 management using the most cutting-edge gene therapy technology, developed from decades of research by noted diabetes leader Hans Sollinger, MD, PhD, Dr hc, at the University of Wisconsin Hospitals and Clinics. Their sole focus is to get a durable, one-time treatment to the millions of people who need it.

SOURCE ENDSULIN

http://www.endsulin.com

See more here:
Top Executives from AveXis Join New Gene Therapy Venture -- This Time Targeting Tens of Millions More Patients - PRNewswire

Gene Therapy for Hemophilia Market will Reach Thriving Value by 2019 to 2028 SoccerNurds – SoccerNurds

A new research study titled Global Gene Therapy for Hemophilia market successfully portrays the entire global scenario as well as a detailed analysis of various regional segments.

Request Sample [emailprotected]https://insights10.com/free-sample-report-inquiry/?id=9158

The Gene Therapy for Hemophilia market research includes an examination of the leading geographies, such as North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific) Latin America ( Mexico, Brazil, Rest of Latin America) and Middle East & Africa (GCC countries, South Africa, and Rest of Middle East & Africa) for the period of 2019 to 2028.

The study on the Gene Therapy for Hemophilia market is a detailed review and presentation of the global industrys drivers, constraints, opportunities, demand factors, market size, historical data forecasts, and trends from 2019 to 2028. The study also assists in the comprehension of global Gene Therapy for Hemophilia market dynamics and structure by defining and evaluating market segments, as well as forecasting global market size.

Top Participants in the Gene Therapy for Hemophilia Market

F. Hoffmann-La Roche AG, Pfizer Inc., BioMarin Pharmaceuticals, uniQure and, Shire PLC.

Global Gene Therapy for Hemophilia Market Segmentation

A. By Class

I. Viral Vector II. Non-Viral Vector

B. Distribution Channel

I. Hospital Pharmacies II. Clinics III. Others

C. Geography

I. North America Market Analysis II. Europe Market Analysis III. Asia-Pacific Market Analysis IV. Middle-East and Africa Market Analysis

View Detail [emailprotected]https://insights10.com/product/global-gene-therapy-hemophilia-market/

Table Of Content of Global Gene Therapy for Hemophilia Market

1. Global Gene Therapy for Hemophilia Market Overview. A. Market Size 2. Market Growth Drivers.. A. Rise in Global Prevalence of Gene Therapy for Hemophilia B. Growing R&D Investments and Reimbursement Policies 3. Gene Therapy for Hemophilia Market Segmentation. A. By Class I. Viral Vector II. Non-Viral Vector B. Distribution Channel I. Hospital Pharmacies II. Clinics III. Others C. Geography I. North America Market Analysis II. Europe Market Analysis III. Asia-Pacific Market Analysis IV. Middle-East and Africa Market Analysis 4. Gene Therapy for Hemophilia Disease Major Market Share.. A. Market Analysis, Insights and Forecast By Revenue 5. Competitive Landscape. A. Major Players B. Products in Pipeline 6. Key Company Profiles A. Pfizer overview, Product & Services, Strategies & Financials B. Shire PLC Company overview, Product & Services, Strategies & Financials C. Roche Company, Product & Services, Strategies & Financials 7. Healthcare Policies and Regulatory Landscape. A. Policy changes and Reimbursement scenario 8. Factors Driving Future Growth.. A. New Trends and Development of Gene Therapy for Hemophilia market B. Future Opportunities 9. Barriers in Future Growth. 10. Conclusion

The report also looks at key players competitive environment in terms of product, value, financial situation, product portfolio, growth strategy, and regional presence. The study includes a value chain analysis and a SWOT analysis to address the issue of whether shareholders should concentrate their efforts and investments in the near future on the Gene Therapy for Hemophilia markets emerging segment. Furthermore, the report is a collective presentation of primary and secondary research findings.

Buy [emailprotected]https://insights10.com/checkout/

Contact:

Email :[emailprotected]

ContactNumber :+91 79 4009 3656

Continue reading here:
Gene Therapy for Hemophilia Market will Reach Thriving Value by 2019 to 2028 SoccerNurds - SoccerNurds

Hemophilia Treatment Market Analysis to 2025 – Growth Trends and Changes Influencing the Industry – Technology Magazine

Global hemophilia treatment market is inclined to accumulate substantial returns over the ensuing years owing to the rising cases of genetic abnormalities and increasing prevalence of hemophilia. Hemophilia is a rare bleeding disorder, which causes incessant or prolonged bleeding after an injury or surgery due to delayed blood clotting. Quality care and efficient treatment can help prevent some serious consequences of the disorder.

Development of advanced treatment technologies such as hemophilia gene therapy is slated to further augment market growth in the succeeding years. Biotechnology companies have been particularly proactive in this regard, working on investigational gene therapies for patients with severe hemophilia A. Successful execution and approval of hemophilia gene therapy will have a substantial effect on hemophilia treatment market size in the future.

Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/2772

Based on product, the recombinant factor concentrates segment is poised to exhibit a growth rate of 5% through 2025, as a result of low disease transmission risks and its prevention of viral infection. Additionally, the product is capable of increasing the replacement therapy safety.

The global hemophilia treatment market from the adult segment recorded revenue worth $6,778.2 million in 2018, as adult patients have high chances of developing moderate to severe hemophilia. As per authentic reports, over 65% of the patients diagnosed with hemophilia are adults.

With regards to the treatment spectrum, the global hemophilia treatment market from the prophylaxis treatment segment registered remuneration of $7,219.9 million in 2018 and is set to account for a major market share over the forecast spell, which can be credited to its effectiveness in treating bleeding episodes and joint pain.

Based on end-use, the hemophilia treatment centers segment is poised to register a growth rate of 4.6% through 2025, which can be attributed to the enhanced care services provided by these centers as compared to clinics and hospitals.

Major industry players have executed several growth strategies such as collaborations, new launches, and mergers to reinforce their position in the global hemophilia treatment market. In 2017, patients with hemophilia A received a more long-lasting option with Roches Hemlibra. The drug received approval from Health Canada for hemophilia A patients deprived of factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce its frequency. Increasing demand for Roches Hemlibra and similar medications among hemophilia A patients would escalate hemophilia treatment industry share.

The competitive landscape of the hemophilia treatment market comprises of companies such as Genentech, Biotest AG, Swedeish Orphan Biovitrum AB, and Sanofi SA, among others. These firms are focusing on expanding their stance in the global market through various strategies including partnerships and innovative product launches.

Request for customization @ https://www.gminsights.com/roc/2772

Partial Chapter of the Table of Content

Chapter 5. Hemophilia Treatment Market, By Product

5.1. Global market share by product, 2018 & 2025

5.2. Recombinant Factor Concentrates

5.2.1. Market size, by region, 2014 2025 (USD Million)

5.2.2. Factor VIII

5.2.2.1. Market size, by region, 2014 2025 (USD Million)

5.2.3. Factor IX

5.2.3.1. Market size, by region, 2014 2025 (USD Million)

5.3. Plasma-derived Factor Concentrates

5.3.1. Market size, by region, 2014 2025 (USD Million)

5.3.2. Factor VIII

5.3.2.1. Market size, by region, 2014 2025 (USD Million)

5.3.3. Factor IX

5.3.3.1. Market size, by region, 2014 2025 (USD Million)

5.4. Extended Half-life Products

5.4.1. Market size, by region, 2014 2025 (USD Million)

5.4.2. Factor VIII

5.4.2.1. Market size, by region, 2014 2025 (USD Million)

5.4.3. Factor IX

5.4.3.1. Market size, by region, 2014 2025 (USD Million)

5.5. Others

5.5.1. Market size, by region, 2014 2025 (USD Million)

Browse full table of contents (TOC) of this report @ https://www.gminsights.com/toc/detail/hemophilia-treatment-market

Read this article:
Hemophilia Treatment Market Analysis to 2025 - Growth Trends and Changes Influencing the Industry - Technology Magazine

Alpha Thalassemia Market Global Production, Growth, Share, Demand and Applications Forecast to 2027 NeighborWebSJ – NeighborWebSJ

Alpha Thalassemia Market Forecast 2020-2027

The Global Alpha Thalassemia Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Alpha Thalassemia Market during the forecast period between 2020 and 2027. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://www.upmarketresearch.com/home/requested_sample/39552

The Report Covers the Following Companies: Bluebird Bio Novartis Kiadis Pharma Acceleron Pharma

By Types: Iron Chelating Drugs Gene Therapy

By Applications: Hospitals Private clinics Other

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://www.upmarketresearch.com/home/request_for_discount/39552

Years Considered to Estimate the Market Size: History Year: 2015-2020 Base Year: 2020 Estimated Year: 2020 Forecast Year: 2020-2027

Important Facts about Alpha Thalassemia Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://www.upmarketresearch.com/home/enquiry_before_buying/39552

About UpMarketResearch: Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearch Name Alex Mathews Email [emailprotected] Organization UpMarketResearch Address 500 East E Street, Ontario, CA 91764, United States.

https://neighborwebsj.com/

Here is the original post:
Alpha Thalassemia Market Global Production, Growth, Share, Demand and Applications Forecast to 2027 NeighborWebSJ - NeighborWebSJ

Global Retinitis Pigmentosa (Retinitis) Market demand with COVID-19 recovery analysis 2021 better delivery process to boost market growth by 2026 KSU…

Retinitis-Pigmentosa-(Retinitis)-MarketLatest research on Global Retinitis Pigmentosa (Retinitis) Market report covers forecast and analysis on a worldwide, regional and country level. The study provides historical information of 2016-2021 together with a forecast from 2021 to 2026 supported by both volume and revenue (USD million). The entire study covers the key drivers and restraints for the Retinitis Pigmentosa (Retinitis) market. this report included a special section on the Impact of COVID19. Also, Retinitis Pigmentosa (Retinitis) Market (By major Key Players, By Types, By Applications, and Leading Regions) Segments outlook, Business assessment, Competition scenario and Trends .The report also gives 360-degree overview of the competitive landscape of the industries.Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries. Players can use this study to explore untapped Retinitis Pigmentosa (Retinitis) markets to extend their reach and create sales opportunities.

Some of the key manufacturers operating in this market include: Sanofi, Amgen, Amarantus Bioscience Holdings, Acucela, Applied Genetic Technologies Corp, Asklepios BioPharmaceutical, Astellas Pharma, Caladrius Biosciences, Dompe Farmaceutici SpA, Dormant Projects, GenSight Biologics SA, Grupo Ferrer Internacional SA, ID Pharma, InFlectis BioScience, Ionis Pharmaceuticals, Mimetogen Pharmaceuticals, Ms Science Corp, Nanovector srl, Novartis AG, Novelion Therapeutics, ProQR Therapeutics, ReNeuron Group Plc, SanBio, Shire (Takeda Pharmaceutical), Spark Therapeutics and More

Download Free PDF Sample Copy of the Report(with covid 19 Impact Analysis): https://www.globmarketreports.com/request-sample/61185

Our Research Analyst implemented a Free PDF Sample Report copy as per your Research Requirement, also including impact analysisofCOVID-19 on Retinitis Pigmentosa (Retinitis) Market Size

Retinitis Pigmentosa (Retinitis) market competitive landscape offers data information and details by companies. Its provides a complete analysis and precise statistics on revenue by the major players participants for the period 2021-2026. The report also illustrates minute details in the Retinitis Pigmentosa (Retinitis) market governing micro and macroeconomic factors that seem to have a dominant and long-term impact, directing the course of popular trends in the global Retinitis Pigmentosa (Retinitis) market.

Based on the type of product, the global Retinitis Pigmentosa (Retinitis) market segmented into: General Treatment Traditional Chinese Medicine Gene Therapy The Surgical Treatment Others

Based on the end-use, the global Retinitis Pigmentosa (Retinitis) market classified into: Hospitals Eye Clinics Others

Regions Covered in the Global Retinitis Pigmentosa (Retinitis) Market:

1. South America Retinitis Pigmentosa (Retinitis) Market Covers Colombia, Brazil, and Argentina. 2. North America Retinitis Pigmentosa (Retinitis) Market Covers Canada, United States, and Mexico. 3. Europe Retinitis Pigmentosa (Retinitis) Market Covers UK, France, Italy, Germany, and Russia. 4. The Middle East and Africa Retinitis Pigmentosa (Retinitis) Market Covers UAE, Saudi Arabia, Egypt, Nigeria, and South Africa. 5. Asia Pacific Retinitis Pigmentosa (Retinitis) Market Covers Korea, Japan, China, Southeast Asia, and India.

Years Considered to Estimate the Market Size: History Year: 2015-2021 Base Year: 2021 Estimated Year: 2021 Forecast Year: 2021-2026

Get Chance of up to 50% Extra Discount@: https://www.globmarketreports.com/request-discount/61185

Reasons to buy:

Some Major TOC Points:

For More Information with including full TOC: https://www.globmarketreports.com/industry-reports/61185/Retinitis-Pigmentosa-(Retinitis)-market

Key highlights of the Retinitis Pigmentosa (Retinitis) Market report: Growth rate Renumeration prediction Consumption graph Market concentration ratio Secondary industry competitors Competitive structure Major restraints Market drivers Regional bifurcation Competitive hierarchy Current market tendencies Market concentration analysis

Customization of the Report: Glob Market Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the Report@: https://www.globmarketreports.com/request-customization/61185

Contact Us: Glob Market Reports 17224 S. Figueroa Street, Gardena, California (CA) 90248,United States Call:+1 915 229 3004(U.S) +44 7452 242832(U.K) Website: http://www.globmarketreports.com

View original post here:
Global Retinitis Pigmentosa (Retinitis) Market demand with COVID-19 recovery analysis 2021 better delivery process to boost market growth by 2026 KSU...

ASCO Names Molecular Profiling in GI Cancers as Advance of the Year – OncLive

Molecular profiling has paved the way for several advances in the treatment of patients with gastrointestinal (GI) malignancies, by identifying critical markers and gene signatures that allow for the delivery of options that are personalized to each tumor. To this end, ASCO has chosen molecular profiling driving progress in GI cancers as its Advance of the Year.1

The organization made the announcement as part of its Clinical Cancer Advances 2021: ASCOs Annual Report on the Progress Against Cancer. The annual update shines a light on important clinical research milestones and policy developments that have been made over the past year; the report also spotlights areas of opportunity to address unmet needs with future efforts.

Molecular profiling tools such as next-generation sequencing give us the ability to identify specific molecular and genomic-targeted treatments that are likely to benefit an individual patient, Howard A. Skip Burris, III, MD, FACP, FASCO, ASCO board chairman, stated in a press release.2 Personalized medicine is becoming a reality.

Although treatments such as surgery, radiotherapy, and chemotherapy have served as the mainstay of treatment in patients with GI cancers, these approaches have limited efficacy and can negatively impact quality of life, according to the report. Although the development of more effective approaches has lagged, the advent of molecular profiling has helped to expand options for these patients; this has resulted in longer survival with minimal adverse effects.

The ability to identify genetic abnormalities, such as mutations, amplifications, or fusions, as well as epigenetic profile, protein expression, or other molecular features has allowed for patients to be matched with the appropriate targeted therapy for their specific tumor. In the past year, HER2-targeted agents have been shown to improve survival in patients with gastric cancer; this approach is showing similar potential in patients with HER2-positive colorectal cancer (CRC).

Several HER2-targeted agents are being examined in patients with GI cancers. For example, the safety and efficacy of the novel HER2-targeted antibodydrug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (Enhertu) was evaluated in patients with HER2-positive gastric or gastroesophageal cancers who had progressed on trastuzumab (Herceptin) as part of the phase 2 DESTINY-Gastric01 trial (NCT03329690).3

Patients who received trastuzumab deruxtecan achieved an objective response rate (ORR) of 51.3% versus 14.3% in those who received chemotherapy. Patients on the trastuzumab deruxtecan arm also experienced an improvement in median overall survival (OS) compared with those on the chemotherapy arm, at 12.5 months versus 8.4 months, respectively (HR, 0.59; 95% CI, 0.39-0.88; P = .0097). The benefit achieved with the ADC led to the January 2021 approval of trastuzumab deruxtecan for use in adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who had previously received a trastuzumab-based regimen.4

Additional data on the agent were presented during the 2020 ASCO Virtual Scientific Program. In thephase 2 DESTINY-CRC01 study (NCT03384940), trastuzumab deruxtecan was examined in 78 patients with HER2-expressing, metastatic CRC who had progressed on 2 or more prior regimens. Here, 1 patient experienced a complete response to treatment, while 23 experienced partial responses.5 In this population, the agent yielded an ORR of 45.3%.

Another advancement was the June 2020 FDA approval of first-line pembrolizumab (Keytruda) for patients with microsatellite instabilityhigh or mismatch repair deficient CRC.6 This regulatory decision on was based on the results from the phase 3 KEYNOTE-177 trial (NCT02563002), in which the PD-1 inhibitor was found to double the time to disease progression versus standard chemotherapy, at 16.5 months versus 8.2 months, respectively.7 Moreover, pembrolizumab resulted in a significant 40% reduction in the risk of disease progression or death versus chemotherapy (HR, 0.60; 95% CI, 0.45-0.80; P = .0004).

The report also examined health inequities in cancer care and clinical research. Although overall cancer-related mortality has decreased in the United States, underserved patient populations still experience lower survival; these populations include black patients, those residing in rural areas, and those with lower incomes and education levels.8,9

Disparities in cancer research is a complex, multifaceted issue requiring a multifactorial response that addresses (1) specific interrelated barriers precluding certain populations from trial participation, and (2) structural and systemic challenges that limit the cancer communitys pursuit of research that would benefit underserved populations, the authors of the report write.

Some obstacles to equitable cancer research can include structural barriers, such as a lack of access to clinics offering clinical trials, as well as transportation and health insurance; clinical barriers, such as eligibility criteria; patient attitudes regarding trials, which could stem from historical inequities and a lack of informed consent; and physician attitudes, such as not offering underserved patients the opportunity to enroll to relevant clinical trials.

The authors of the report suggest several strategies to potentially improve equity in clinical cancer research. To this end, ASCO and Friends of Cancer Research have been working together to finalize 4 new Guidance for Industry documents that would broaden eligibility criteria for clinical trials by lowering the minimum participation age and to include patients with brain metastases who have been treated and are stable. Additionally, expanded guidelines would include patients with human immunodeficiency virus and hepatitis B and C virus, and recommend less restrictive renal, cardiac, and hepatic function criteria.

Other efforts include umbrella and basket trial designs, broadening trial availability, improving patient education and navigation, developing new consent strategies, and providing more financial assistance plans.

Among the numerous developments listed in the report, authors underscored the importance of artificial intelligence (AI) technology, a complex field of medical research that has grown exponentially in recent years. Authors of the report noted that AI technology can potentially be used to integrate a wealth of data points into a clinically meaningful context.

Currently, several types of AI are being utilized in the field of oncology, including deep learning methods that are able to identify relationships within data to solve complex problems through the utilization of algorithms in an iterative process. This technology could help to advance diagnostic, therapeutic, and translational research in both cancer prevention and treatment.

Key areas of interest include the development of deep learning methodologies to help with diagnosing cancer based on biospecimen analysis; using AI to improve radiographic imaging, analysis, and reporting; and using these systems to integrate vast amounts of clinical data to assist in the clinical decision-making process and measure outcomes.

It will be critical to educate oncologist about the fundamentals, advantages, and potential pitfalls of AI and deep learning techniques to support effective application in real-world cancer care, according to the authors of the report.

The coronavirus disease 2019 (COVID-19) pandemic has provided a unique opportunity for investigators to reconsider how clinical cancer research can be conducted and to examine disparities that exist with regard to clinical trial participation. Within the first weeks of the pandemic, 60% of US research institutions froze screening and enrollment for clinical trial research.10

To address this, investigators and institutions, with help from the FDA and the National Comprehensive Cancer Network, took action. To avoid the shutdown of clinical trials, investigator and sponsors found ways to allow for some flexibility, while preserving the integrity of the research. Remote patient monitoring and drug administration were permitted, and guidance was created to allow for virtual consent using e-signatures and limited collection of research-only biospecimens. Moreover, patients were allowed to have their local healthcare providers perform blood draws and imaging scans for these efforts.

Although the pandemic spotlighted existing racial and socioeconomic disparities, it also underscored the ability of the oncology community to rapidly respond to significant, unexpected disruptions to care and research efforts.

This same ingenuity and flexibility can and should be applied to improving health equity for all individuals, so that right treatment truly is delivered to the right patient at the right time, everywhere, the authors of the report wrote.

Go here to see the original:
ASCO Names Molecular Profiling in GI Cancers as Advance of the Year - OncLive

Circularity Healthcare Announces Expansion with Global CRO of Series of Successful Pivotal Human Clinical Trials to Study Use of D’OXYVA for Rapid,…

PASADENA, Calif., Feb. 1, 2021 /PRNewswire/ --Circularity Healthcare announced it had successfully executed a contract with the Professional Educational Research Institute (PERI) in 2020 to immediately begin a new clinical trial to study the use of D'OXYVA to help prevent amputations and treat human diabetic foot ulcers at one-tenth the time and cost, and at least five times the efficacy of competing modalities. A widely recognized global clinical research organization (CRO), PERI will specifically study at multiple sites at prestigious U.S. universities the use of D'OXYVA to help address the recent epidemic of DFUs occurring in diabetic patients due to long-term pandemic quarantines and stay-at-home orders. Manufactured by Circularity, D'OXYVA is a painless, noninvasive transdermal delivery system used in minutes to significantly improve blood perfusion, tissue oxygenation, and wound healing even where standard treatments have failed.

"D'OXYVA's pivotal human clinical trial for complete healing of diabetic foot ulcershas been approved by the Western Institutional Review Board (WIRB), the largest in the world, and will include over a dozen high profile research sites at top U.S. universities and clinics," said Senior Sales and Marketing Manager for Circularity, Jennifer Boadilla-Pelaez, RN. "Thousands of competing products in the past nearly twenty-five years have failed in achieving what D'OXYVAhas obtained in terms of regulatory approvals, clinical safety and efficacy in the past seven years. This is truly a game-changing milestone, not just for the company itself, but the entire medical community and the world and a preliminary report with meaningful results is expected within6 months from starting the pivotal trial," said Dr. Charles M. Zelen, PERI's CEO.

DFUs are a major wound complication arising out of diabetes mellitus and occur in 313% of global diabetes patients, affecting millions of people. DFUs are caused by a variety of factors including decreased activity, diminished blood circulation, and people with underlying health conditions like diabetes are at higher risk for complications from COVID-19. Healthcare workers can expect to see far more instances of this persistent problem, especially with quarantine lockdowns, and it represents a significant health and economic risk to both patients and the overall healthcare system. Effective treatments that can reduce DFU recovery time, like D'OXYVA, are absolutely crucial to combatting this newest wound epidemic.

About Circularity Healthcare LLC

Circularity Healthcare is an emerging world leader in proprietary circulatory health and noninvasive delivery technologies, committed to helping improve quality of life by developing, manufacturing, and marketing medical, pharmaceutical, and consumer health products. Circularity specializes in groundbreaking noninvasive technologies for affordable and portable transdermal delivery systems, and is currently pursuing regulatory approval worldwide as a way of treating cardiovascular and microcirculatory blood flow issues, as well as immune and autonomic nervous system disorders. Learn more at: http://www.CircularityHealthcare.com.

About Professional Education and Research Institute, Inc.

PERI was established in 2005 as a premier CRO to manage Phase I - IV clinical trials around the world. PERI conducts clinical trials in both pharmaceutical and orthopedic research and performs specialty research in diabetic wound care, venous leg disease, neuropathy, peripheral vascular disease and gene therapy. One of the most unique advantages of choosing PERI as a partner in clinical trial management is a feature few CRO's can match, which is our contracted sites throughout the United States, including IBC-certified sites. Learn more at: http://www.periedu.com

Media Contact: Jennifer Boadilla-Pelaez 626-240-0956 [emailprotected]

SOURCE Circularity Healthcare LLC

http://www.CircularityHealthcare.com

See original here:
Circularity Healthcare Announces Expansion with Global CRO of Series of Successful Pivotal Human Clinical Trials to Study Use of D'OXYVA for Rapid,...

Parkinson’s disease treatment Market Global Industry Analysis, Size, Share, Trends, Segmentation and Forecast 2021 2027 KSU | The Sentinel…

Parkinsons disease treatment Market unveils a succinct analysis of the market size, regional spectrum and revenue forecast about the Parkinsons disease treatment market. Furthermore, the report points out major challenges and the latest growth plans embraced by key manufacturers that constitute the competitive spectrum of this business domain.

Global Parkinsons disease treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027

Get Sample Copy of The Report@https://brandessenceresearch.com/requestSample/PostId/62

Scope of Market Reports

Parkinsons disease is a neuro degenerative disorder in which parts of the brain become progressively damaged over many years. It is a type of movement disorder. It occurs when nerve tissue unable to produce a chemical named Dopamine which is used to send signals that help you move your body. Parkinsons disease usually developed for aged people i.e. above 60 years, but it can also start earlier. It is more common in men than in women. The cause of Parkinsons disease is unknown, but researchers think that both genetic and environmental factors are involved. Primary symptoms include tremors, Stiffness, Slowness, impaired balance, mild memory & Thinking problem and shuffling gait. Secondary symptoms include Anxiety, Depression, Fatigue, Low blood pressure, muscle cramp, Speech & communication problem, skin & Dental Problem and Dizziness, and Dementia. Risk of Parkinsons disease increases with age and the disease mainly affects person over 50 years of age. The development of Parkinsons disease and the degree of destruction differ from person to person. Many people with Parkinsons disease live long productive lives, whereas others become disabled much more quickly. As symptoms worsen, it may become difficult to walk, talk, and complete simple tasks. Malnutrition and weight maintenance is common problem for people with Parkinsons disease. There is no test to diagnose Parkinsons disease with certainty. Treatment options include medication or surgical treatment. Combination of Levodopa with carbidopa is considered as a gold standard for symptomatic treatment of Parkinsons disease. Surgical treatment options include deep brain stimulation and Carbidopa/levodopa enteral suspension therapy but surgical therapy is effective only for patients who have previously responded to Levodopa therapy. Commercially available drugs for treatment of Parkinsons disease are Sinemet, Safinamide, Rotigotine, Ropinirole, Pramiprexol, Amantidine, Cycloset, Parlodel (Bromocriptine Mesylate), Rytary, Azilect, Northera, Stalevo, Comtess/Comtan and others. More than past decade, huge improvement has been made in the treatment of Parkinsons disease such as identification of new therapeutic targets through genetic research, understanding the common mutations that contribute to Parkinsons disease etc.

Global Parkinsons diseases Treatment Market report is segmented on the basis of Medication, Medical devices, End user, Distribution Channels and Geography. Based on Medication Global Parkinsons disease Treatment Market is classified into Dopamine Precursors, Peripheral Decarboxylase Inhibitors, COMT (Catechol-O-methyltransferase) Inhibitors, MAO (Monoamine Oxidase), Inhibitors and Others (anticholinergics, antihistaminics etc.)

On the basis of Medical Devices Global Parkinsons disease Treatment Market is classified into Deep Brain Stimulation (DBS) Devices, Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices and others. On the basis of End User Global Parkinsons disease Treatment Market is classified into Hospitals, Homecare setting, Clinics and Others. On the basis of Distribution Channel Global Parkinsons disease Drug Market is classified into Retail Pharmacies, Online Pharmacies, Hospital Pharmacies and Drug Stores.

The regions covered in Global Parkinsons diseases Treatment Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Market Dynamics

Global Parkinsons disease Treatment Market is mainly driven by growing prevalence of Parkinsons disease and government funding for research on Parkinsons disease. The increase in number of geriatric population and technological advancements such as combination therapies for prolong action of continuous dopaminergic stimulation drugs, gene therapy, neural transplantation are few other causes which are possible to boost the Parkinsons disease Treatment market. However some restraints like availability of alternative treatments is expected to hold back market and expiry of patents for several drugs such as Stalevo, Azilect, Rytary, Comtan etc. can cause the termination of Parkinsons disease Treatment market. High cost of treatment such as 14.4 Billion USD and lack of expertise for early diagnosis is likely to restrict the market growth.

Also lack of novel and successful therapies in the market to reduce the risk of mortality restraints for this market. The opportunities for Global Parkinsons disease Treatment market includes upcoming technologies like surface EMG (Electromyography) sensors, Pulse oximetry sensors, development in personalized medicine along with huge investment in anti-Parkinsons drugs research will boost the global Parkinsons disease Treatment market. Also development of novel drugs and combination therapy with less side effects and better survival rates is expected to increase the global Parkinsons disease Treatment market.

Get Methodology of Report @https://brandessenceresearch.com/requestMethodology/PostId/62

Europe is likely to achieve the largest share of the global Parkinsons disease treatment market, which is expected to be followed by North America with a sizeable market share. High knowledge about the treatment, increase in expenditure for Research & Development, favorable medicinal reimbursement regulations and policies, the high occurrence of Parkinsons disease, the rapidly growing geriatric population and potential medical pipeline products are likely to contribute to the major share of Europe in Global Parkinsons disease treatment market. The global Parkinsons disease treatment market in the Asia Pacific is anticipated to develop at a profitable rate. The market share of the global Parkinsons disease treatment market is to be expected to grasp by China and Japan in the Asia Pacific, due to the large population of elderly people who are affected with Parkinsons disease.

Furthermore, increase in awareness of disease and government initiatives for improving health care facilities are expected to boost the regional market to a certain extent.

By Medication Analysis Dopamine Precursor, Peripheral Decarboxylase Inhibitors, COMT (Catechol-O-methyltransferase) Inhibitors, MAO(monoamine oxidase) Inhibitors, Others (anticholinergics, antihistaminics etc.)

By Medical Devices Analysis Deep Brain Stimulation (DBS) Devices, Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices, Others

By End User Analysis Hospitals, Clinics, Homecare setting, Others

By Distribution Channel Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, Drug Store

North America, US, Mexico, Chily, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, South Korea, Japan, India, Southeast Asia, Latin America, Brazil, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa

Get Full Report :@https://brandessenceresearch.com/chemical-materials/parkinsons-disease-treatment-market

Related Report @https://www.prnewswire.com/news-releases/at-19-71cagr-zero-trust-security-market-size-is-projected-to-reach-94-35-billion-by-2027says-brandessence-market-research-301213906.html

https://www.marketwatch.com/press-release/at-1971-cagr-zero-trust-security-market-size-is-projected-to-reach-9435-billion-by-2027-says-brandessence-market-research-2021-01-25?tesla=y

https://www.marketwatch.com/press-release/at-cagr-of-1222-remote-patient-monitoring-market-size-is-expected-to-reach-usd-293638-million-by-2025-says-brandessence-market-research-2021-01-12?tesla=y

About Us:

Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us atsales@industrystatsreport.com

Website:https://brandessenceresearch.com/

Article:https://businessstatsnews.com

Blog:http://www.dailyindustrywatch.com

Blog:https://marketsize.biz

Blog:https://technologyindustrynews.com

Blog:https://marketstatsreport.com

View post:
Parkinson's disease treatment Market Global Industry Analysis, Size, Share, Trends, Segmentation and Forecast 2021 2027 KSU | The Sentinel...

The Head And Neck Cancer Therapeutics Market to shirk economic slowdown between 2016 and 2024 Murphy’s Hockey Law – Murphy’s Hockey Law

Cancers of squamous cells present in the linings of larynx, throat, nose, salivary glands, lips, mouth are collectively called as head and neck cancers. According to World Health Organization (WHO), globally more than 550,000 new cases of head and neck cancer are diagnosed per year with around 300,000 deaths annually. Head and neck cancer is the sixth most common type of cancer and accounts for 56% of all cancers. Treatment of head and neck cancer presents a significant challenge to physicians as the choice of treatment varies from patient to patient and location of the tumor. Head and neck cancers ate often treated with surgery, but the complexity of facial structures and functions limits the surgical treatments.

Request to Sample report @https://www.persistencemarketresearch.com/samples/11734

Surgery for head and neck cancer changes some of the functions such as chewing, swallowing, talking, etc. Surgical therapy in combination with radiation therapy is the most preferred treatment regime by physicians. However, currently available treatment options for head and neck cancer do not result in improvement in survival rate, and head and neck cancer survival rate has decreased from 80% to 50%in last ten years. Recent developments in advanced chemotherapy and radiotherapy allow preserving some of the functions of the face. The introduction of targeted molecular therapy such as gene therapy, monoclonal antibodies, antibody drug conjugates, etc. has opened up huge potential for the growth of head and neck cancer therapeutics market.

Growing incidence of head and neck cancer and demand for cost-effective treatment options are the factors driving the growth of global head and neck cancer therapeutic market. According to Globocan 2012, globally, 521,983 new cases of the lip, oral cavity, and larynx cancer were diagnosed in 2012. Advancements in technology and development of new targeted molecules are believed to play the crucial role in the growth of global head and neck cancer therapeutics market over the forecast period.

Request PMR insights on measuring the impact of COVID-19 coronavirus across industries.

The global market for anti-neoplastic agents is segmented on basis of treatment type, disease indication, end user and geography:

Based on treatment type, global head and neck cancer therapeutics market has been segmented as follow:

Based on disease indication, global head and neck cancer therapeutics market has been segmented as follow:

Based on end user, global head and neck cancer therapeutics market has been segmented as follow:

Increasing smoking rate, tobacco consumption and incidence of HPV-caused cancers are the factors primarily responsible for growing prevalence of head and neck cancers such as oral cavity cancer, nasopharyngeal cancer, etc. Based on treatment type, global head and neck cancer therapeutics market is classified as chemotherapy, radiation therapy, and surgery. Surgery is expected to lead the global market for head and neck cancer therapeutics over the forecast period as it is the choice of therapy by physicians. Radiation therapy is used to prevent the recurrence of cancer and is expected to contribute second largest share in the global head and neck cancer therapeutics market. Chemotherapy is used as an adjunct to other therapies and thus hold little share in global head and neck cancer therapeutics market.

Based on disease indication, global head and neck cancer therapeutics market has been segmented into laryngeal cancer, lip and oral cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, salivary gland cancer and others. Lip and oral cavity cancer indication type segment is expected to contribute the highest share in the global market for head and neck cancer therapeutics market owing to the high global prevalence of cancer. GLOBOCAN 2012 reports_bk_01_01_2020 the highest prevalence of 3.1% in 2012 affecting 467,157 people affected by lip and oral cancer globally.

Based on the end user, the global head and neck cancer therapeutics market has been segmented into hospitals, specialty clinics, and ambulatory surgical centers. Hospital end user segment is anticipated to contribute the maximum share among end users.

Request For TOC @https://www.persistencemarketresearch.com/toc/11734

Based on the regional presence, global head and neck cancer therapeutics market is segmented into five key regions viz. North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America will continue to dominate the global head and neck cancer therapeutics market for due to high prevalence HPV-induced cancers and high smoking rate. Europe is expected to hold second largest market share in global head and neck cancer therapeutics market.

Some of the major players operating in the global head and neck cancer therapeutics market are,

For in-depth competitive analysis, buy [emailprotected]https://www.persistencemarketresearch.com/checkout/11734

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved Beg Persistence Market Research Address 305 Broadway, 7th Floor, New York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Sales[emailprotected] Websitehttps://www.persistencemarketresearch.com

https://murphyshockeylaw.net/

See the rest here:
The Head And Neck Cancer Therapeutics Market to shirk economic slowdown between 2016 and 2024 Murphy's Hockey Law - Murphy's Hockey Law